Feasibility of repairing glomerular basement membrane defects in alport syndrome

Journal of the American Society of Nephrology

Volumn 25, Issue 4, 2014, Pages 687-692

  Lin, Xiaobo ^a   Suh, Jung Hee ^a   Go, Gloriosa ^a   Miner, Jeffrey H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; DOXYCYCLINE; GREEN FLUORESCENT PROTEIN; LAMININ; PODOCIN; AUTOANTIGEN; GT(ROSA)26SOR NON CODING RNA, MOUSE; GT(ROSA)26SOR NON-CODING RNA, MOUSE; TYPE IV COLLAGEN ALPHA3 CHAIN; UNTRANSLATED RNA;

ALPORT SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE COURSE; FEASIBILITY STUDY; GLOMERULUS BASEMENT MEMBRANE; KIDNEY DISEASE; KIDNEY FUNCTION; LIFE EXTENSION; MOUSE; NONHUMAN; PLASTICITY; PODOCYTE; PRIORITY JOURNAL; TRANSGENE; ANIMAL; BASEMENT MEMBRANE; DISEASE MODEL; GENETICS; GLOMERULUS; HUMAN; NEPHRITIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; AUTOANTIGENS; BASEMENT MEMBRANE; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; HUMANS; KIDNEY GLOMERULUS; MICE; NEPHRITIS, HEREDITARY; RNA, UNTRANSLATED; TRANSGENES;

EID: 84901399937     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013070798     Document Type: Article

References (33)

1. Miner JH: The glomerular basement membrane. Exp Cell Res 318: 973-978, 2012
2. Kashtan CE: Alport syndrome. Kidney Int Suppl 58: S69-S71,1997
3. Abrahamson DR, Hudson BG, Stroganova L, Borza DB, St John PL: Cellularorigins of type IV collagen networks in developing glo-meruli. J Am Soc Nephrol 20: 1471-1479, 2009
4. Heidet L, Cai Y, Guicharnaud L, Antignac C, Gubler MC: Glomerular expression of type IV collagen chains in normal and X-linked Alport syndrome kidneys. Am J Pathol 156: 1901 - 1910, 2000
5. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Alport's syndrome, Goodpasture's syndrome, and type IV collagen. NEnglJMed348: 2543-2556, 2003
6. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, Höcker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, Dötsch J, Müller-Wiefel DE, Hoyer P, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Müller GA, Weber M; Study Group Members of the Gesellschaft für Pädiatrische Nephrologie: Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81: 494-501, 2012
7. Baumal R, Thorner P, Valli VE, McInnes R, Marrano P, Jacobs R, Binnington A, Bloedow AG: Renal disease in carrierfemale dogs with X-linked hereditarynephritis. Implications for female patients with this disease. Am J Pathol 139: 751-764, 1991
8. Cosgrove D, Kalluri R, Miner JH, Segal Y, Borza DB: Choosing amouse model to study the molecular pathobiology of Alport glo-merulonephritis. Kidney Int 71: 615-618, 2007
9. Grodecki KM, Gains MJ, Baumal R, Osmond DH, CotterB, Valli VE, Jacobs RM : Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comp Pathol 117: 209-225, 1997
10. Gross O, Friede T, Hilgers R, Görlitz A, Gavénis K, Ahmed R, Dürr U: Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: The double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT Alport Trial in Pediatric patients. ISRN Pediatr 2012: 436046, 2012
11. Cosgrove D, Meehan DT, Grunkemeyer JA, Kornak JM, Sayers R, Hunter WJ, Samuelson GC: Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome. Genes Dev 10: 2981-2992, 1996
12. Miner JH, Sanes JR: Molecularand functional defects in kidneys of mice lacking collagen alpha 3(IV): Implications for Alportsyndrome. J Cell Biol135: 1403-1413, 1996
13. Cosgrove D, Rodgers K, Meehan D, Miller C, Bovard K, Gilroy A, Gardner H, Kotelianski V, Gotwals P, Amatucci A, Kalluri R: Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 157: 1649-1659, 2000
14. Rao VH, Meehan DT, Delimont D, Nakajima M, Wada T, Gratton MA, Cosgrove D: Role for macrophage metalloelastase in glomer-ular basement membrane damage associated with alport syndrome. Am J Pathol 169: 32-46, 2006
15. Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, Werner MC, Shield CF 3rd, Werb Z, Kalluri R: Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 3: e100, 2006
16. Lebleu VS, Sugimoto H, Miller CA, Gattone VH 2nd, Kalluri R: Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. LabInvest 88: 284-292, 2008
17. Ninichuk V, Gross O, Reichel C, Khandoga A, Pawar RD, Ciubar R, Segerer S, Belemezova E, Radomska E, Luckow B, Perez de Lema G, Murphy PM, Gao JL, Henger A, Kretzler M, Horuk R, Weber M, Krombach F, Schlöndorff D, Anders HJ: Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. JAm Soc Nephrol 16: 977-985, 2005
18. Clauss S, Gross O, Kulkarni O, Avila-Ferrufino A, Radomska E, Segerer S, Eulberg D, Klussmann S, Anders HJ: Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropa-thy. JPathol 218: 40-17, 2009
19. Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Kalluri R: Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci USA 103: 73217326, 2006
20. LeBleu V, Sugimoto H, Mundel TM, Gerami-Naini B, Finan E, Miller CA, Gattone VH 2nd, Lu L, Shield CF 3rd, Folkman J, Kalluri R: Stem cell therapies benefit Alportsyndrome. J Am Soc Nephrol 20: 2359-2370, 2009
21. Prodromidi EI, Poulsom R, Jeffery R, Roufosse CA, Pollard PJ, Pusey CD, Cook HT: Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 24: 2448-2455, 2006
22. Katayama K, Kawano M, Naito I, Ishikawa H, Sado Y, Asakawa N, Murata T, Oosugi K, Kiyohara M, Ishikawa E, Ito M, Nomura S: Irradiation prolongs survival of Alport mice. JAmSocNephrol19: 1692-1700, 2008
23. Gross O, Borza DB, Anders HJ, Licht C, Weber M, Segerer S, Torra R, Gubler MC, Heidet L, Harvey S, Cosgrove D, Lees G, Kashtan C, Gregory M, Savige J, Ding J, Thorner P, Abrahamson DR, Antignac C, Tryggvason K, Hudson B, Miner JH: Stem cell therapy for Alport syndrome: The hope beyond the hype. Nephrol Dial Transplant 24: 731-734, 2009
24. Sedrakyan S, Da Sacco S, Milanesi A, Shiri L, Petrosyan A, Varimezova R, Warburton D, Lemley KV, De Filippo RE, Perin L: Injection of amniotic fluid stem cells delays progression of renal fibrosis. J Am Soc Nephrol 23:661-673,2012
25. Heikkila P, Parpala T, Lukkarinen O, Weber M, Tryggvason K: Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidneyperfusion system - frst steps towards gene therapy of Alport syndrome. GeneTher 3:21-27,1996
26. Heidet L, Borza DB, Jouin M, Sich M, Mattei MG, Sado Y, Hudson BG, Hastie N, Antignac C, Gubler MC: Ahuman-mousechimera ofthe alpha3alpha4alpha5(IV) collagen protomer rescues the renal phenotype in Col4a3-/- Alport mice. Am J Pathol 163:1633-1644, 2003
27. Belteki G, Haigh J, Kabacs N, Haigh K, Sison K, Costantini F, Whitsett J, Quaggin SE, Nagy A: Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Res 33: e51, 2005
28. Shigehara T, Zaragoza C, Kitiyakara C, Takahashi H, Lu H, Moeller M, Holzman LB, Kopp JB: Inducible podocyte-specificgene expression in transgenic mice. J Am Soc Nephrol 14: 1998-2003, 2003
29. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, Fuchs E: Defining the epithelial stem cell niche in skin. Science303: 359-363, 2004
30. Eremina V, Wong MA, Cui S, Schwartz L, Quaggin SE: Glomerular-specific gene excision in vivo. JAm Soc Nephrol 13: 788-793, 2002
31. Zhou X, Vink M, Klaver B, Berkhout B, Das AT: Optimization of the Tet-On system for regulated gene expression through viral evolution. GeneTher 13: 1382-1390,2006
32. Goldberg S, Adair-Kirk TL, Senior RM, Miner JH: Maintenance of glomerular fltration barrier integrity requires laminin alpha5. J Am Soc Nephrol 21: 579-586, 2010
33. Andrews KL, Mudd JL, Li C, Miner JH: Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 160: 721-730, 2002